<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where	n/a
For commercial reagents, provide supplier		No antibodies were used in this
name, catalogue number and RRID, if available.		study.

Cell materials	Yes (indicate where	n/a
Cell lines: Provide species information, strain.		No cell lines were used in this
Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID		study.
Primary cultures: Provide species, strain, sex of		No primary cultures were used in
origin, genetic modification status.		this study.

Experimental animals	Yes (indicate where	n/a
Laboratory animals: Provide species, strain, sex, age,		No laboratory animals were used
genetic modification status. Provide accession		in this study.
number in repository OR supplier name, catalog		
number, clone number, OR RRID		
Animal observed in or captured from the		No animal observed in or captured
field: Provide species, sex and age where		from the field were used in this
possible		study.
Model organisms: Provide Accession number		No model organisms were used in
in repository (where relevant) OR RRID		this study

Plants and microbes	Yes (indicate where	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		No plants were used in this study.
Microbes: provide species and strain, unique accession number if available, and source		No microbes were used in this study.

Human research participants	Yes (indicate where	n/a
Identify authority granting ethics approval (IRB or		This study did not involve any
equivalent committee(s), provide reference number		human research participants.
for approval.		
Provide statement confirming informed consent		This study did not involve any
obtained from study participants.		human research participants.
Report on age and sex for all study participants.		This study did not involve any
, , , ,		human research participants.

Design

Study protocol	Yes (indicate where	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.	,	This study is not clinical trials.
Laboratory protocol	Yes (indicate where	n/a
Provide DOI or other citation details if detailed step- by-step protocols are available.		No laboratory protocol was used in this study.
Experimental study design (statistics details)	Yes (indicate where	n/a
State whether and how the following have been done, or if they were not carried out.	·	
Sample size determination		No sample size determination was carried out.
Randomisation		No randomization was carried out.
Blinding		No Blinding was carried out.
Inclusion/exclusion criteria		No inclusion or exclusion criteria was carried out.
Sample definition and in-laboratory replication	Yes (indicate where	n/a
State number of times the experiment was replicated in laboratory		No laboratory experiment was performed.
Define whether data describe technical or biological replicates		No laboratory experiment was performed.
Ethics	Yes (indicate where	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	res (maicace where	The study did not involve any human participant.
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		The study did not involve any experimental animals.
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		The study did not involve any specimen and field samples.
Dual Use Research of Concern (DURC)	Yes (indicate where	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	,	The study is not subject to dual use research.

<u>Analysis</u>

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	RNA-seq data and corresponding clinical information of patients with primary GBM used in this study are publicly available. Only the data with detailed survival information and radiation therapy record was included (Page 8, Line 123-133, Section" Materials and Methods", Paragraph "Database").	

Statistics	Yes (indicate where provided:	n/a
Describe statistical tests used and justify choice of	The Kaplan-Meier method was used	
tests.	for survival analysis and p < 0.05	
	was regarded as significant by the	
	log-rank test (Page 10, Line 169-	
	171, Section" Materials and	
	Methods", Paragraph "Statistical	
	analysis").	
	The limma package of R software	
	was used to define differential	
	expressed gene (Page 9, Line 136-	
	138, Section "Materials and	
	Methods, Paragraph "Identification	
	of DEGs").	
	To detect the prognostic value of	
	DEGs, the survival package of R	
	software was used for univariate	
	Cox regression analysis and p < 0.05	
	was regarded as significant (Page	
	10, Line 171-173, Section "Materials	
	and Methods, Paragraph "Statistical	
	analysis").	

Data Availability	Yes (indicate where provided:	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		RNA-seq data and corresponding clinical information of GAM patients used in this study are publicly available.
If data are publicly available, provide accession number in repository or DOI or URL.		RNA-seq data and corresponding clinical information of GAM patients used in this study are publicly available.
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	TCGA, CGGA and ImmuneScore and StromalScore of TCGA GBM are publicly available at https://tcga-data.nci.nih.gov/tcga/, http://www.cgga.org.cn/, and https://bioinformatics.mdanderson. org/estimate/, respectively.(Page 8, Line 128-133, Section "Materials and Methods, Paragraph "Database").	

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.		No newly generated code and software were used in this study.
If code is publicly available, provide accession number in repository, or DOI or URL.		No newly generated code and software were used in this study

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article Information: http://dx.doi.org/10.21037/TCR-20-2476.	